1FW2:F:F- (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.4258

Change

+0.03 (+2.12)%

Market Cap

USD 6.04B

Volume

208.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

N/A

USD 601.26B
VX1:F Vertex Pharmaceuticals Incorpo..

N/A

USD 114.63B
RGO:F Regeneron Pharmaceuticals Inc

N/A

USD 106.63B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 88.75B
CSJ:F CSL Limited

N/A

USD 88.09B
0QF:F Moderna Inc

N/A

USD 42.67B
UNC:F UCB SA

N/A

USD 26.08B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 26.00B
1AE:F Argen-X

N/A

USD 24.59B
1AEA:F argenx SE

N/A

USD 24.49B

ETFs Containing 1FW2:F

FID First Trust Intl Multi-As.. 1.96 % 0.69 %

N/A

USD 0.08B
WDIV:AU SPDR S&P Global Dividend 1.45 % 0.00 %

N/A

USD 0.25B
EWH iShares MSCI Hong Kong ET.. 0.00 % 0.48 %

N/A

USD 0.49B
FGD First Trust Dow Jones Glo.. 0.00 % 0.58 %

N/A

USD 0.53B
WDIV SPDR® S&P Global Dividen.. 0.00 % 0.40 %

N/A

USD 0.20B
3110:HK Global X Hang Seng High D.. 0.00 % 0.00 %

N/A

USD 2.16B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.51% 12% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.51% 12% F 4% F
Trailing 12 Months  
Capital Gain -66.70% 18% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.70% 18% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -21.04% 18% F 7% C-
Dividend Return -21.04% 18% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.00% 51% F 37% F
Risk Adjusted Return -65.73% 12% F 6% D-
Market Capitalization 6.04B 94% A 81% B-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.